Navigation Links
Harrisvaccines Awarded National Institute of Food and Agriculture Grant for Swine Disease Research
Date:10/1/2013

AMES, Iowa, Oct. 1, 2013 /PRNewswire/ -- Ames, Iowa-based vaccine producer, Harrisvaccines, today announced it has been awarded a grant from the USDA National Institute of Food and Agriculture (NIFA) for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) research. This project is supported by Agriculture and Food Research Initiative Grant no. 2013-67015-21307 from the USDA National Institute of Food and Agriculture.

The grant, titled Proteomics-defined Porcine Reproductive and Respiratory Syndrome Virus Immunoproteome, will be a two-year project, beginning on October 1, 2013. Dr. Mark Mogler, Head of Research for Harrisvaccines, and Dr. Kurt Kamrud collaborated in achieving the grant with Dr. Manohar John of PathoVacs. Dr. Mogler will be serving as Project Director.

The basic research project will focus on a new way of looking for protective determinants of the PRRS virus. Harrisvaccines will be generating protein fragment libraries of PRRSV strains and the PRRSV protein fragment libraries will be screened using innovative technology developed by their collaborator on the project, Dr. John.

"Dr. John has a novel technology that allows him to screen thousands of antigens at a time," said Dr. Mogler. "This will be very beneficial, because rather than looking at only one antigen at a time, we will be able to look at tens of thousands simultaneously."

During the first year of the project, Harrisvaccines will be generating the fragments and creating fragment libraries for screening; screening will also be done during the first year. The second year of the project will mainly consist of data analysis and confirmatory testing.

At the end of the two years, Dr. Mogler is confident that Harrisvaccines will be able to characterize the immune response to PRRSV proteins by identifying reactiv
'/>"/>

SOURCE Harrisvaccines
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lpath Awarded NIH SBIR Grant for Lpathomab
2. Rudolf Kingslake Medal Awarded by SPIE for TNO Paper on Color Image Fusion for Night-Vision Applications
3. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
4. Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinsons Disease
5. VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
6. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
7. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
8. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
9. Boehringer Laboratories LLC Awarded HPG Contract for Clinical Suction Regulators
10. ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein
11. Puritan Awarded New Canadian Patent for PurFlock® Ultra Flocked Swab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported financial and operational results for the ... of 2009, PharmAthene recognized revenues of $5.5 million compared ... Revenues for the most recent quarter consisted primarily ...
... (OTC Bulletin Board: DORB) (DOR or the Company), a ... the first quarter of 2009. DOR,s revenues for the ... to $0.7 million for the first quarter of 2008. ... research and development amounts drawn down from DOR,s NIH ...
... Study and Orphan Drug DesignationROCKVILLE, Md., May 15 ... pharmaceutical company developing therapeutics for the treatment of cancer ... candidates at the American Society of Clinical Oncology (ASCO) ... 2, 2009 in Orlando, Florida. Presentations include both ...
Cached Biology Technology:PharmAthene Reports First Quarter 2009 Financial and Operational Results 2PharmAthene Reports First Quarter 2009 Financial and Operational Results 3PharmAthene Reports First Quarter 2009 Financial and Operational Results 4PharmAthene Reports First Quarter 2009 Financial and Operational Results 5PharmAthene Reports First Quarter 2009 Financial and Operational Results 6PharmAthene Reports First Quarter 2009 Financial and Operational Results 7DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 2EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 3EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 4EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 5
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... the speed that ice travels in more than 200 outlet ... the 21st century could be significantly less than the upper ... a paper funded by the National Science Foundation (NSF) and ... While the study indicates that a melting Greenland,s contributions to ...
... Boston, MA A new study by Harvard School of ... high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not ... be harmful. , This is the first study to ... resides on the surface of HDL cholesterol may increase the ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) and Memorial ... that commonly occurring large chromosomal deletions that are ... functionally linked genes whose loss, they posit, confers a ... closely at one large deletion -- a so-called copy-number ...
Cached Biology News:Analysis of speed of Greenland glaciers gives new insight for rising sea level 2Analysis of speed of Greenland glaciers gives new insight for rising sea level 3Some HDL, or 'good' cholesterol, may not protect against heart disease 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 3
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Biology Products: